On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.31 which represents a slight increase of $0.15 or 6.94% from the prior close of $2.16. The stock opened at $2.3 and ...

AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...

AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational ...

Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...

Vigil Neuroscience, Inc.（纳斯达克代码：VIGL）的总裁兼首席执行官Ivana Magovcevic-Liebisch最近购买了该公司5,000股普通股。这家临床阶段生物科技公司目前市值为9200万美元。根据 InvestingPro 的分析，该股票目前的交易价格低于其公允价值，表明可能存在上涨机会。这些股票于12月5日以2.34美元的加权平均价格购入，总交易金额为11,7 ...

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...

As of 12:34:05 PM EST. Market Open. Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.

在其他近期新闻中，Alector Inc.遭遇重大挫折，其针对潜在阿尔茨海默病治疗药物AL002的二期INVOKE-2试验未能达到主要终点，导致该项目被终止。这促使Morgan Stanley将Alector的股票评级从"与大盘持平"下调至"减持"，并将目标价下调至3.00美元。尽管如此，H.C.

William Blair initiated coverage of Vigil Neuroscience (VIGL) with an Outperform rating and $18.67 fair value estimate. Vigil ...

As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...